Dr Claire Morgan

Research Highlights

1. Coupe, B., Brotto, M., Clegg, R., Daniels, H., Griffiths, J., Hildebrandt, T., Young, R., Thomas, R., Morgan, C. 2019 How do we train healthcare professionals to integrate genomics into their practice? MSc in genomic medicine, Swansea University, Wales Future Healthcare Journal 6 Suppl 2 21 21

   https://cronfa.swan.ac.uk/Record/cronfa52382 doi: 10.7861/futurehealth.6-2-s21
2. Morgan, C. 2019 Genomics for Paediatric Cancer The Welsh Paediatric Journal 50 3 7

   https://cronfa.swan.ac.uk/Record/cronfa50949
3. Morgan, C., Swithenbank, L., Whiteland, H., Doak, S. 2018 Increased ARF6 activation correlates with HGF stimulation in non-invasive prostate cancer cells Journal of Cancer Metastasis and Treatment 4 8 46

   https://cronfa.swan.ac.uk/Record/cronfa43606 doi: 10.20517/2394-4722.2018.19
4. Murtaza, B., Doak, S., Morgan, C., Nadeem, M., Al-Ghanim, K., Shakoori, A. 2016 A Crosstalk BetweenK ras(Kirsten Rat Sarcoma Viral Oncogene Homologue) and Adherence Molecular Complex Leads to Disassociation of Cells-A Possible Contribution Towards Metastasis in Colorectal Cancer Journal of Cellular Biochemistry 117 10 2340 2345

   https://cronfa.swan.ac.uk/Record/cronfa26729 doi: 10.1002/jcb.25531
5. Swithenbank, L., Morgan, C. 2017 Role of antimicrobial peptides in lung cancer therapy Journal of antimicrobial agents 3 134

   https://cronfa.swan.ac.uk/Record/cronfa32046 doi: 10.4172/2472-1212.1000134
6. Avancini, D., Menzies, G., Morgan, C., Wills, J., Johnson, G., white, P., Lewis, P. 2015 MutAIT: An online genetic toxicology portal and analysis tool. Mutagenesis

   https://cronfa.swan.ac.uk/Record/cronfa22667
7. Ismail, H., Morgan, C., Griffiths, P., Williams, J., Jenkins, G. 2016 A Newly Developed Nested PCR Assay for the Detection of Helicobacter pylori in the Oral Cavity Journal of Clinical Gastroenterology 50 1 17 22

   https://cronfa.swan.ac.uk/Record/cronfa20007 doi: 10.1097/MCG.0000000000000310
8. Morgan, C., Jones, R., Bertelli, G. 2015 Effects of Zoledronic acid and Docetaxel on Small GTP-binding proteins in prostate cancer Tumour Biology

   https://cronfa.swan.ac.uk/Record/cronfa20006 doi: 10.1007/s13277-015-3140-9
9. Quinton, A., Lewis, P., Ali, P., Morgan, C., Bertelli, G., Lewis, P., Morgan, C. 2013 A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma Medical Oncology 30 3

   https://cronfa.swan.ac.uk/Record/cronfa18429 doi: 10.1007/s12032-013-0661-1
10. Morgan, C., Nigam, Y. 2013 Naturally derived factors and their role in the promotion of angiogenesis for the healing of chronic wounds Angiogenesis

    https://cronfa.swan.ac.uk/Record/cronfa14340 doi: 10.1007/s10456-013-9341-1
11. Morgan, C., Lewis, P., Jones, R., Bertelli, G., Thomas, G., Leonard, R. 2007 Thein vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer Acta Oncologica 46 5 669 677

    https://cronfa.swan.ac.uk/Record/cronfa11901 doi: 10.1080/02841860600996447
12. Morgan, C., Lewis, P. 2006 iMARS—Mutation analysis reporting software: An analysis of spontaneous cII mutation spectra Mutation Research/Genetic Toxicology and Environmental Mutagenesis 603 1 15 26

    https://cronfa.swan.ac.uk/Record/cronfa11906 doi: 10.1016/j.mrgentox.2005.09.010
13. Morgan, C., Alazawi, W., Sirieix, P., Freeman, T., Coleman, N., Fitzgerald, R. 2004 In Vitro Acid Exposure has a Differential Effect on Apoptotic and Proliferative Pathways in a Barrett's Adenocarcinoma Cell Line The American Journal of Gastroenterology 99 2 218 224

    https://cronfa.swan.ac.uk/Record/cronfa11903 doi: 10.1111/j.1572-0241.2004.04054.x
14. Morgan, C. 2001 The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay Mutation Research 498 (1-2) 135 144

    https://cronfa.swan.ac.uk/Record/cronfa11905
15. Morgan, C., Jenkins, G., Ashton, T., Griffiths, A., Baxter, J., Parry, E., Parry, J., Jenkins, G., Morgan, C., Baxter, J. 2003 Detection of p53 mutations in precancerous gastric tissue British Journal of Cancer 89 7 1314 1319

    https://cronfa.swan.ac.uk/Record/cronfa1365 doi: 10.1038/sj.bjc.6601302
16. Walker, K., Morgan, C., Doak, S., Dunstan, P. 2012 Quantum Dots for Multiplexed Detection and Characterisation of Prostate Cancer Cells Using a Scanning Near-Field Optical Microscope PLoS ONE 7 2 e31592

    https://cronfa.swan.ac.uk/Record/cronfa7294 doi: 10.1371/journal.pone.0031592
17. Bexfield, A., Bond, A., Morgan, C., Wagstaff, J., Newton, R., Ratcliffe, N., Dudley, E., Nigam, Y., Nigam, Y., Dudley, E., Morgan, C. 2010 Amino acid derivatives fromLucilia sericataexcretions/secretions may contribute to the beneficial effects of maggot therapy via increased angiogenesis British Journal of Dermatology 162 3 554 562

    https://cronfa.swan.ac.uk/Record/cronfa8919 doi: 10.1111/j.1365-2133.2009.09530.x
18. Morgan, C., Jeremiah, S., Wagstaff, J. 2009 Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells Microvascular Research 78 2 141 141

    https://cronfa.swan.ac.uk/Record/cronfa9999 doi: 10.1016/j.mvr.2009.05.001
19. Morgan, C., Jeremiah, S., Wagstaff, J., Wagstaff, J., Morgan, C. 2009 Metronomic administration of ibandronate and its anti-angiogenic effects in vitro Microvascular Research 78 453 458

    https://cronfa.swan.ac.uk/Record/cronfa10000
20. Morgan, C., Wagstaff, J., Wagstaff, J., Morgan, C. 2009 Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases? Acta Oncologica 48 882 889

    https://cronfa.swan.ac.uk/Record/cronfa10077
21. André, F., Morgan, C., Jenkins, S., Kynaston, H., Doak, S. 2013 The Role of Adhesion Molecules as Biomarkers for the Aggressive Prostate Cancer Phenotype PLoS ONE 8 12 e81666

    https://cronfa.swan.ac.uk/Record/cronfa16740 doi: 10.1371/journal.pone.0081666
22. Whiteland, H., Spencer-Harty, S., Thomas, D., Davies, C., Morgan, C., Kynaston, H., Bose, P., Fenn, N., Lewis, P., Bodger, O., Jenkins, S., Doak, S. 2013 Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer Experimental and Molecular Pathology 95 2 220 226

    https://cronfa.swan.ac.uk/Record/cronfa16741 doi: 10.1016/j.yexmp.2013.07.010
23. Whiteland, H., Lewis, P., Doak, S., Morgan, C. 2014 A role for STEAP2 in prostate cancer progression Clinical & Experimental Metastasis 1 12

    https://cronfa.swan.ac.uk/Record/cronfa18791 doi: 10.1007/s10585-014-9679-9
24. Bertelli, G., Quinton, A., Lewis, P., Ali, P., Morgan, C., Lewis, P., Morgan, C. 2015 Reply to the letter to the editor 'Measured and estimated glomerular filtration rate for carboplatin dose calculation' by Cathomas et al. Annals of Oncology 26 1 249 250

    https://cronfa.swan.ac.uk/Record/cronfa19277 doi: 10.1093/annonc/mdu475
25. Nigam, Y., Morgan, C., Nigam, Y., Morgan, C. 2015 Does maggot therapy promote wound healing? The clinical and cellular evidence Journal of the European Academy of Dermatology and Venereology

    https://cronfa.swan.ac.uk/Record/cronfa25452 doi: 10.1111/jdv.13534
26. Morgan, C., Lewis, P., Hopkins, L., Burnell, S., Kynaston, H., Doak, S. 2015 Increased expression of ARF GTPases in prostate cancer tissue SpringerPlus 4 1

    https://cronfa.swan.ac.uk/Record/cronfa34906 doi: 10.1186/s40064-015-1136-y
27. Burnell, S., Spencer-Harty, S., Howarth, S., Bodger, O., Kynaston, H., Morgan, C., Doak, S. 2018 STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells Scientific Reports 8 1

    https://cronfa.swan.ac.uk/Record/cronfa39502 doi: 10.1038/s41598-018-24655-x

    https://www.nature.com/articles/s41598-018-24655-x
28. Evans, R., Morgan, C., Jones, N., Nigam, Y. 2019 Human Growth Factor Homologues, Detected in Externalised Secretions of Medicinal Larvae, Could be Responsible for Maggot-Induced Wound Healing International Journal of Research in Pharmacy and Biosciences 6 4 1 10

    https://cronfa.swan.ac.uk/Record/cronfa50559

    http://ijrpb.org/papers/v6-i5/1.pdf
29. Burnell, S., Spencer-Harty, S., Howarth, S., Bodger, O., Kynaston, H., Morgan, C., Doak, S. 2019 Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer PLOS ONE 14 8 e0220456

    https://cronfa.swan.ac.uk/Record/cronfa51465 doi: 10.1371/journal.pone.0220456

All Research

• Pre-operative assessment of invasive lobular carcinoma of the breast - comparing Digital Breast Tomosynthesis with C-view, and magnetic resonance imaging. (current)

  MD

  Other supervisor: Prof Paul Lewis

• Bacterial Targeting and Manipulation of Tumour Cell Metabolism (current)

  PhD

  Other supervisor: Prof Paul Dyson

• Investigation of the utility of optical spectroscopy for management of chronic respiratory disease through investigation of sputum mucin glycosylation patterns (awarded 2019)

  PhD

  Other supervisor: Prof Paul Lewis

• 'The role of STEAP2 in Prostate Cancer Progression' (awarded 2017)

  PhD

  Other supervisor: Prof Shareen Doak

• “DEVELOPING BACTERIAL MEDIATED RNAi AS A THERAPY FOR PANCREATIC CANCER” (awarded 2019)

  MSc

  Other supervisor: Prof Paul Dyson

• 'Unbiased and targeted metabolomic approaches to biomarker discovery for pancreatic cancer' (awarded 2018)

  MSc

  Other supervisor: Dr Ed Dudley

• The anti-cancer potentials of LSer-Cec5 and Temporin A on non-small cell lung cancer. (awarded 2019)

  MSc

  Other supervisor: Prof Paul Lewis

• PM-149 Fundamental Genetics and Evolution

  The module will provide a foundation in genetics and evolution. Concepts such as DNA discovery, structure and replication, gene transcription and translation, mechanisms of gene transmission, genome organisation, epigenetic modifications and mutations will be covered with an appreciation of how how these mechanisms have an impact on human disease and antibiotic resistance. The latter part of the module will start with the work of Plato, Cuvier, Lamarck, Wallace and Darwin and how they (and others) influenced the development of an evolutionary theory framework. Using this knowledge the module will then look at the processes involved in speciation and how they can be applied at both the gene and whole organismal level.

• PM-254 Doctors, patients & the goals of medicine

  TBC

• PM-267 Genes on Drugs: Pharmacogenomics

  Genes affect how the body reacts to drugs as well as how they are absorbed, metabolized and eliminated. You will learn how variation in genes encoding proteins involved in these processes affect how drugs work ¿ or don¿t ¿ therapeutically. By understanding these factors, you will gain insight into the emerging field of personalized medicine and learn how individualized drug design and selection can improve therapeutic efficacy, safety and sustainability.

• PM-317 Genetics of Cancer

  This module will provide students with an advanced understanding about the genetic mechanisms involved in carcinogenesis, and how these underlying processes and molecules affect the human body.

• PM-338 Teaching Science In Schools

  This module is for students with an interest in entering teaching, and involves placements in local schools The student will engage both in observation and in various teaching activities. The module will be assessed through various methods including a written report and the teachers report.

• PM-342 Advances in Pharmacology

  Pharmacology is the science of how drugs act on the body and how the body acts on drugs. Pharmacology investigates the chemical and physical properties of drugs, how those properties confer actions on living tissues and how those actions affect health and disease. The beneficial, therapeutic effects of drugs will be discussed, but also some negative consequences of drug administration, such as toxicity, addiction and microbial drug-resistance.

• PM-344 Capstone Project

  The aim of this module is to provide a capstone experience to students¿ learning, through participating in their own enquiry-based research project. Depending on the student's employability strand within the programme, the project may be laboratory, data, or education-based, but it will always involve a research question that is drawn from the literature, focused on a topic relevant to medical science. It will ask a novel research question and involve the critical analysis of research findings. Students will refine their oral and written communication skills to a graduate level through creating an introductory presentation on the project background, and a written dissertation and oral presentation on their research conclusions.

• PM-354 Cancer Pharmacology

  Cancer remains a significant cause of mortality in the modern world. Current and emerging chemotherapies, and the rationale, experimental, and clinical evidence of the pathways or molecules targeted will be explored. Causes of treatment-related side effects, and the therapies used to address these, will be discussed along with the mechanisms that lead to anti-cancer drug resistance.

• PM-402 Advanced Research Project B

  The advanced research project is a key component of the final year of study, providing students with experience of conducting cutting-edge research in the Institute of Life Science and Centre for Nanohealth over an 9-month period. The project will fall into one of the current medically-related research themes: Biomarkers and Genes; Microbes and Immunity; Devices. Students will employ a range of advanced analytical procedures to investigate a specific topic. In addition, they will gain experience in preparing a research proposal and presenting their data in various formats. Research topics will be assigned that are appropriate to a specific degree title. For example, a Genetics student could be assigned a project investigating gene function in an insect vector of a tropical disease, using the technique of RNA interference. The advanced research project is divided between 2 modules, PM-400 and PM-402. PM-402 comprises the final written dissertation.

• PMGM13 Ethical, Legal and Societal Issues (ELSI) in Applied Genomics

  This module will provide students with an understanding of the legal, regulatory & governance frameworks associated with medical genomics and the use of genomic data. It will equip students to explore and evaluate the main ethical, legal and social issues (ELSI) involved in: genomic testing and the wider implications for the patient and their families; precision medicine; and the use of genomic data for population research.

• PMGM14 Cancer Genomics

  This module covers the molecular mechanisms that underlie cancer development, growth and metastasis, and the differences between different cancers. It will explore the different molecular and cellular actions of anti-cancer treatments, the genomic factors affecting response and resistance to treatment, and the research approaches to anti-cancer drug design and development. Broad situations which confer a high cancer risk to a person and/or to other members of the same family will be discussed in the context of how genomic information may be integrated into cancer screening programmes. This module will prepare the students to interrogate the cancer data sets from the 100,000 Genomes Project as well as to interrogate cancer genomic datasets in general.

• PMGM16 Genomics of Common and Rare Inherited Disease

  This module will provide an introduction to the clinical presentation and manifestations of rare inherited and common diseases, and considers the patient and family perspective with respect to the role and impact of genomics. It reviews traditional and current strategies and techniques used to identify genes responsible for both common multifactorial and rare inherited diseases.

• PMGM17 Research Dissertation

  The module is for students to build on their previous knowledge, skills and experience by undertaking a medical genomics research project.

• PMGM18 Critical Literature Review

  This module will allow students to carry out a critical and in-depth evaluation of previous research based on a specific subject related to genomics

• Cancer Research UK Pioneer Award: A Novel RNAi Therapy for Solid Tumours 2016

  , with Professor Paul Dyson, £188,000

• Clinical Investigation: Spectroscopic Technology to Predict Exacerbations and Diagnose COPD) 2016

  , with Professor Paul Lewis, £194,000

• Welsh Government: In vivo testing and market assessment of an RNAi- based therapy for solid tumours 2016

  , with Professor Paul Dyson, £74,971

• National Institute for Social Care and Health: Investigation of the utility of optical spectroscopy for management of chronic respiratory disease through investigation of sputum mucin glycosylation patterns 2014

  , with Professor Paul Lewis , £65,611

• Welsh Government: Developing novel SMO inhibitor to target Hedgehog signalling pathway in cancer 2017

  , with Professor Yuqin Wang, £50,000

• Agor IP: Translating New RNAi Therapy for Solid Tumours for commercialisation 2017

  , with Professor Paul Dyson, £50,000

• Welsh Government: Potency Optimisation of Luc0023 2014

  , £54, 720

• Welsh Government: Bacterial Mediated RNAi as a new therapy to target advanced prostate cancer 2014

  , £44,000

• St David’s Medical Foundation: Investigating the role of Tight Junctions as biomarkers for prostate cancer progression 2010

  , £26,743

• Associate Professor , Swansea University Medical School

  2018 - Present

• Senior Lecturer, Swansea University Medical School

  2013 - 2018

• Genetics Tutor, Swansea University Medical School

  2011 - 2013

• Post Doctoral Research Assistant , Swansea University Medical School

  2004 - 2011

• Post Doctoral Research Assistant , Hutchison , MRC, Cancer Cell Unit, Cambridge

  2002 - 2004

• External Examiner, Kings and St George’s University of London

  2019 - 2022

• External Examiner , Cardiff Metropolitan

  2019 - 2022

• External Examiner, Aberystwyth University

  2020 - 2023

• Local Representative , Genetics Society

  2016 - Present

• University Representative , Biology Education Research Group

  2017 - Present

• Invited Member, Genomics Partnership Wales

  2019 - Present

• Invited Member, Wales Gene Park Strategic Advisory Group

  2020 - Present